ASH 2014 - San Francisco - CML - Chronic Myeloid Leukemia
CML Program
Saturday, December 6, 2014
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
632. Chronic Myeloid Leukemia: Therapy: Poster I
Sunday, December 7, 2014
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
632. Chronic Myeloid Leukemia: Outcomes With TKI Therapy
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia: Therapy: Poster II
Monday, December 8, 2014
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Molecular Targets and Drug Sensitivity in Myeloid Diseases
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Biological Pathways Relevant to Molecular Pharmacology and Drug Resistance/Sensitivity
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Strategies to Circumvent Therapy Resistance
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Disease Progression and the Microenvironment: Therapeutic Implications
632. Chronic Myeloid Leukemia: Prognosis and Therapy
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Poster III
Tuesday, December 9, 2014
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Molecular Mechanisms of Myeloid Malignancy
632. Chronic Myeloid Leukemia: Therapy: TKI cessation, monitoring and resistance
Saturday, December 6, 2014
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster I
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster I
632. Chronic Myeloid Leukemia: Therapy: Poster I
Sunday, December 7, 2014
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster II
632. Chronic Myeloid Leukemia: Outcomes With TKI Therapy
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia: Therapy: Poster II
Monday, December 8, 2014
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Molecular Targets and Drug Sensitivity in Myeloid Diseases
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Biological Pathways Relevant to Molecular Pharmacology and Drug Resistance/Sensitivity
604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Strategies to Circumvent Therapy Resistance
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Disease Progression and the Microenvironment: Therapeutic Implications
632. Chronic Myeloid Leukemia: Prognosis and Therapy
631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia: Therapy: Poster III
Tuesday, December 9, 2014
602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Molecular Mechanisms of Myeloid Malignancy
632. Chronic Myeloid Leukemia: Therapy: TKI cessation, monitoring and resistance
Forums and Patient associations 'reports
ASH 2014 – CMLsupport - Some abstracts interesting and useful
ASH 2014 – CML Advocates Network - Report #1: Stopping CML treatment for therapy-free remission
ASH 2014 – CML Advocates Network : Optimizing CML therapy
ASH 2014 - The CML Society of Canada - Live Updates Direct from The Conference
NOTES
An NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML
2014, SPIRIT2, NewCastle Universisty
ASH 2014 – CMLsupport - Some abstracts interesting and useful
ASH 2014 – CML Advocates Network - Report #1: Stopping CML treatment for therapy-free remission
ASH 2014 – CML Advocates Network : Optimizing CML therapy
ASH 2014 - The CML Society of Canada - Live Updates Direct from The Conference
NOTES
An NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML
2014, SPIRIT2, NewCastle Universisty
SOME INTERESTING ABSTRACTS FOR CML
Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study
Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials
Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related both to Low Number and Impaired Function of NK-Cells
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis
Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukaemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc
Cooperative Targeting of Bcl-2 Family Proteins by ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells
Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukaemia (CML) in Chronic Phase (CP)
Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukaemia (CML) Patients
Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukaemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
The Experience of the International Registry for Chronic Myeloid Leukaemia (CML) in Children and Adolescents (I-CML-Ped Study): Prognostic Consideration
Return to other ASH Annual Meetings
Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study
Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials
Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related both to Low Number and Impaired Function of NK-Cells
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis
Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukaemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc
Cooperative Targeting of Bcl-2 Family Proteins by ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells
Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukaemia (CML) in Chronic Phase (CP)
Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukaemia (CML) Patients
Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukaemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
The Experience of the International Registry for Chronic Myeloid Leukaemia (CML) in Children and Adolescents (I-CML-Ped Study): Prognostic Consideration
Return to other ASH Annual Meetings
